JP2012021001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012021001A5 JP2012021001A5 JP2011161229A JP2011161229A JP2012021001A5 JP 2012021001 A5 JP2012021001 A5 JP 2012021001A5 JP 2011161229 A JP2011161229 A JP 2011161229A JP 2011161229 A JP2011161229 A JP 2011161229A JP 2012021001 A5 JP2012021001 A5 JP 2012021001A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tnfα
- antibody
- composition according
- low dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 5
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010051728 Bone erosion Diseases 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 230000001627 detrimental effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 102000057041 human TNF Human genes 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 208000018934 joint symptom Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42126202P | 2002-10-24 | 2002-10-24 | |
| US60/421,262 | 2002-10-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004547181A Division JP5594803B2 (ja) | 2002-10-24 | 2003-10-24 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014181968A Division JP2015028040A (ja) | 2002-10-24 | 2014-09-08 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012021001A JP2012021001A (ja) | 2012-02-02 |
| JP2012021001A5 true JP2012021001A5 (enExample) | 2012-09-27 |
| JP5676386B2 JP5676386B2 (ja) | 2015-02-25 |
Family
ID=32176690
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004547181A Expired - Fee Related JP5594803B2 (ja) | 2002-10-24 | 2003-10-24 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
| JP2011161229A Expired - Fee Related JP5676386B2 (ja) | 2002-10-24 | 2011-07-22 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
| JP2014181968A Pending JP2015028040A (ja) | 2002-10-24 | 2014-09-08 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004547181A Expired - Fee Related JP5594803B2 (ja) | 2002-10-24 | 2003-10-24 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014181968A Pending JP2015028040A (ja) | 2002-10-24 | 2014-09-08 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8846046B2 (enExample) |
| EP (3) | EP1578439B1 (enExample) |
| JP (3) | JP5594803B2 (enExample) |
| KR (4) | KR20110000757A (enExample) |
| CN (2) | CN103623408A (enExample) |
| AR (2) | AR045710A1 (enExample) |
| AT (1) | ATE517632T1 (enExample) |
| AU (2) | AU2003301522B8 (enExample) |
| BR (1) | BR0315597A (enExample) |
| CA (1) | CA2497909A1 (enExample) |
| DK (1) | DK1578439T3 (enExample) |
| ES (1) | ES2370351T3 (enExample) |
| MX (1) | MXPA05004344A (enExample) |
| MY (1) | MY150740A (enExample) |
| NZ (3) | NZ539332A (enExample) |
| PE (1) | PE20040751A1 (enExample) |
| PL (2) | PL213215B1 (enExample) |
| PT (1) | PT1578439E (enExample) |
| SA (1) | SA04240497A (enExample) |
| SI (1) | SI1578439T1 (enExample) |
| TW (3) | TW201345552A (enExample) |
| UY (1) | UY28041A1 (enExample) |
| WO (1) | WO2004037205A2 (enExample) |
| ZA (1) | ZA200502983B (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| BRPI9707379C8 (pt) | 1996-02-09 | 2017-12-12 | Abbott Biotech Ltd | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| MY151032A (en) * | 2002-07-19 | 2014-03-31 | Abbott Lab S A | Treatment of tnf? related disorders |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| CN102060806A (zh) * | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
| KR20150055116A (ko) | 2005-05-16 | 2015-05-20 | 애브비 바이오테크놀로지 리미티드 | 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도 |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| NZ567286A (en) * | 2005-11-01 | 2012-03-30 | Abbott Biotechnolgy Ltd | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
| WO2007058990A2 (en) * | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| US9889156B2 (en) | 2006-01-19 | 2018-02-13 | The Regents Of The University Of Michigan | Method for treating noise-induced hearing loss (NIHL) |
| US9770433B2 (en) | 2006-01-19 | 2017-09-26 | The Regents Of The University Of Michigan | Composition and method for treating tinnitus |
| US9919008B2 (en) | 2006-01-19 | 2018-03-20 | The Regents Of The University Of Michigan | Method for treating age-related hearing loss (ARHL) |
| US10238599B2 (en) | 2006-01-19 | 2019-03-26 | The Regents Of The University Of Michigan | Composition and method for treating congenital cytomegalovirus induced hearing loss |
| USRE46372E1 (en) | 2006-01-19 | 2017-04-25 | The Regents Of The Univerity Of Michigan | Method for treating hearing loss |
| US8927528B2 (en) | 2006-01-19 | 2015-01-06 | The Regents Of The University Of Michigan | Composition for treating hearing loss |
| US7951845B2 (en) | 2006-01-19 | 2011-05-31 | The Regents Of The University Of Michigan | Composition and method of treating hearing loss |
| US8338397B2 (en) | 2006-01-19 | 2012-12-25 | The Regents Of The University Of Michigan | Composition and method of treating side effects from antibiotic treatment |
| NZ611859A (en) | 2006-04-05 | 2014-12-24 | Abbvie Biotechnology Ltd | Antibody purification |
| US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| WO2007120656A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
| US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| JP5535623B2 (ja) | 2006-06-30 | 2014-07-02 | アッヴィ バイオテクノロジー リミテッド | 自動注射装置 |
| EP2684895A1 (en) * | 2006-10-27 | 2014-01-15 | AbbVie Biotechnology Ltd | Crystalline anti-hTNFalpha antibodies |
| EP2165194A4 (en) * | 2007-05-31 | 2010-09-08 | Abbott Lab | BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES |
| AU2008259513B2 (en) * | 2007-06-06 | 2014-07-24 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| CA2693771A1 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor |
| WO2009020654A1 (en) | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| TWI543768B (zh) | 2007-11-30 | 2016-08-01 | 艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| CA2710333A1 (en) * | 2008-01-03 | 2009-07-09 | Abbott Biotechnology Ltd. | Predicting long-term efficacy of a compound in the treatment of psoriasis |
| SG2013054218A (en) | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| ES2507086T3 (es) * | 2008-03-27 | 2014-10-14 | Toyama Chemical Co., Ltd. | Uso de derivado de benzofenona o la sal del mismo e inhibidor de TNF-alfa combinados y composición farmacéutica que contiene el derivado o la sal del mismo y el inhibidor |
| JP5677411B2 (ja) | 2009-04-29 | 2015-02-25 | アッヴィ バイオテクノロジー リミテッド | 自動注入機器 |
| WO2010129469A1 (en) * | 2009-05-04 | 2010-11-11 | Abbott Biotechnology Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| NZ600069A (en) | 2009-12-15 | 2015-02-27 | Abbvie Biotechnology Ltd | Improved firing button for automatic injection device |
| RS57543B1 (sr) | 2010-06-03 | 2018-10-31 | Abbvie Biotechnology Ltd | Primene i kompozicije za lečenje hidradenitis suppurativa (hs) |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| JP5919606B2 (ja) | 2010-11-11 | 2016-05-18 | アッヴィ バイオテクノロジー リミテッド | 改良型高濃度抗ｔｎｆアルファ抗体液体製剤 |
| CN106075664B (zh) | 2011-01-24 | 2019-07-02 | 艾伯维生物技术有限公司 | 具有模制抓握面的自动注射装置 |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| EP2520934A1 (en) * | 2011-05-04 | 2012-11-07 | CellMade SAS | Method for finding active pharmaceutical ingredients for the treatment of deseases associated with increased or decreased cytokine pathway activity |
| WO2012150325A1 (en) * | 2011-05-04 | 2012-11-08 | Cellmade Sas | Method for finding active pharmaceutical ingredients for the treatment of diseases associated with increased or decreased cytokine pathway activity |
| CN109608543A (zh) * | 2011-10-20 | 2019-04-12 | 艾斯巴技术-诺华有限责任公司 | 稳定的多抗原结合抗体 |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
| EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| RU2676303C2 (ru) * | 2013-07-11 | 2018-12-27 | Новартис Аг | Использование антагониста vegf для лечения ретролентальной фиброплазии |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| WO2015057910A1 (en) | 2013-10-16 | 2015-04-23 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| EP3145951A1 (en) | 2014-06-24 | 2017-03-29 | InSight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
| SG11201701039PA (en) * | 2014-08-14 | 2017-03-30 | Hoffmann La Roche | Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 |
| EP3247718B1 (en) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| CA2981103A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| DK4089113T3 (da) | 2015-03-31 | 2024-02-05 | Sorriso Pharmaceuticals Inc | Polypeptider |
| KR102789821B1 (ko) | 2015-03-31 | 2025-04-02 | 소리소 파마슈티컬스 인크. | 프로테아제-절단가능 링커를 갖는 펩티드 구조물 |
| EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
| CN104887687A (zh) * | 2015-05-27 | 2015-09-09 | 南京医科大学第一附属医院 | 美莎拉嗪在制备治疗坏疽性脓皮病的药物中的应用 |
| WO2017136433A1 (en) | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| LT3464318T (lt) | 2016-06-02 | 2021-06-25 | Abbvie Inc. | Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2019005898A1 (en) * | 2017-06-27 | 2019-01-03 | Ohio State Innovation Foundation | LIPONUCLEOTID THERAPY FOR COPD |
| PE20201286A1 (es) | 2017-12-01 | 2020-11-24 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados de este |
| EP3986571A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| AU2020296979A1 (en) | 2019-06-21 | 2022-02-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58501544A (ja) | 1981-09-08 | 1983-09-16 | ザ ロツクフエラ− ユニヴア−シテイ | エンドトキシン誘発メディエ−タ−（ショック検定）によるリポプロティンリパ−ゼの抑圧 |
| US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| IL73883A (en) | 1984-12-20 | 1990-12-23 | Yeda Res & Dev | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
| US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| EP0212489B1 (en) | 1985-08-16 | 1994-11-30 | The Rockefeller University | Anabolic activity modulator and uses thereof |
| US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| EP0230574A3 (en) | 1986-01-31 | 1989-03-22 | Yale University | Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| US5237054A (en) | 1987-02-20 | 1993-08-17 | Akzo Pharma | Stabilized aqueous composition containing antibodies |
| WO1989011298A1 (en) | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Formulation for antibody reagents |
| AU626572B2 (en) | 1988-07-18 | 1992-08-06 | Chiron Corporation | Monoclonal antibodies reactive with cachectin |
| WO1990001191A2 (en) | 1988-07-27 | 1990-02-08 | Bmc Software, Inc. | Improved data transmission optimizer |
| US4897465A (en) | 1988-10-12 | 1990-01-30 | Abbott Laboratories | Enrichment and concentration of proteins by ultrafiltration |
| EP0366043B1 (en) | 1988-10-24 | 1994-03-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibody |
| ES2096553T3 (es) | 1988-12-19 | 1997-03-16 | American Cyanamid Co | Metodo para el tratamiento de choque endotoxico en un animal mamifero. |
| EP0486526B2 (en) | 1989-08-07 | 2001-03-07 | Peptech Limited | Tumour necrosis factor binding ligands |
| US5998378A (en) | 1989-08-16 | 1999-12-07 | Chiron Corporation | Compositions for the inhibition of TNF hormone formation and uses thereof |
| GB8921123D0 (en) | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
| JPH0791318B2 (ja) | 1989-09-21 | 1995-10-04 | 三井東圧化学株式会社 | 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤 |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| DE4037604A1 (de) | 1990-04-25 | 1991-10-31 | Bayer Ag | Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| EP0608212A1 (en) | 1990-08-27 | 1994-08-03 | Peptide Technology Ltd | Method of treating viral infection |
| GB2279077B (en) * | 1990-12-21 | 1995-06-14 | Celltech Ltd | Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US5994510A (en) | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
| GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| CA2106079C (en) | 1991-03-15 | 2000-04-25 | Robert C. Thompson | Pegylation of polypeptides |
| US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| DE69233701T2 (de) | 1991-03-18 | 2008-04-10 | New York University | Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| ES2123515T3 (es) | 1991-03-29 | 1999-01-16 | Immunex Corp | Antagonistas de citoquinas a base de proteinas virales aisladas. |
| US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| AU3244693A (en) | 1991-12-17 | 1993-07-19 | Schering Corporation | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock |
| WO1993019751A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| DK0585705T3 (da) | 1992-08-28 | 1999-07-26 | Bayer Ag | Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis |
| KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
| US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| JPH08509203A (ja) | 1992-10-15 | 1996-10-01 | ダナ−ファーバー キャンサー インステテュート インコーポレイテッド | ＴＮＦ−α作用の拮抗剤を用いる肥満関連糖尿病▲ＩＩ▼型のインスリン耐性の治療 |
| DE122009000074I1 (de) | 1993-03-05 | 2011-12-01 | Bayer Healthcare Ag | Humane monoklonale anti-TNF alpha Antikorper. |
| DE4307508A1 (de) | 1993-03-10 | 1994-09-15 | Knoll Ag | Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche) |
| WO1994029347A1 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Antibody fragments in therapy |
| FR2708467B1 (fr) | 1993-07-30 | 1995-10-20 | Pasteur Merieux Serums Vacc | Préparations d'immunoglobulines stabilisées et procédé pour leur préparation. |
| EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| NZ278607A (en) | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| JPH09509835A (ja) | 1994-03-04 | 1997-10-07 | メルク エンド カンパニー インコーポレーテッド | アラニン走査型突然変異誘発によるｉｎ ｖｉｔｒｏ抗体アフィニティー成熟 |
| ZA955642B (en) | 1994-07-07 | 1997-05-06 | Ortho Pharma Corp | Lyophilized imaging agent formulation |
| GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| DK1516628T3 (da) | 1995-07-27 | 2013-09-08 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| BRPI9707379C8 (pt) | 1996-02-09 | 2017-12-12 | Abbott Biotech Ltd | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| GB9705810D0 (en) | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
| WO1998044948A2 (en) | 1997-04-07 | 1998-10-15 | Cangene Corporation | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| CN1520885A (zh) | 1997-10-23 | 2004-08-18 | ������ҩ��ʽ���� | 可室温贮存的免疫球蛋白静脉注射制剂 |
| WO1999037329A1 (en) | 1998-01-22 | 1999-07-29 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| US6015557A (en) * | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US6419944B2 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6177077B1 (en) | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| US6537549B2 (en) * | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6423321B2 (en) * | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
| EP1041072B1 (en) | 1999-03-31 | 2003-07-16 | Pfizer Products Inc. | Dioxocyclopentyl hydroxamic acids |
| US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2000066160A1 (fr) | 1999-04-28 | 2000-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation |
| JP2002544175A (ja) | 1999-05-05 | 2002-12-24 | エラン コーポレーシヨン ピーエルシー | 核酸系薬剤の送達促進法 |
| WO2001047554A1 (fr) | 1999-12-28 | 2001-07-05 | Chugai Seiyaku Kabushiki Kaisha | Compositions d'anticorps stables et preparations pour injection |
| US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| WO2002011753A1 (en) | 2000-08-04 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Protein injection preparations |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| EP2311492B1 (en) | 2000-08-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing stabilized preparations |
| SE0003045D0 (sv) | 2000-08-29 | 2000-08-29 | Probi Ab | New method |
| ES2332402T5 (es) | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
| MXPA03004883A (es) | 2000-12-01 | 2004-05-04 | Battelle Memorial Institute | Metodo para la estabilizacion de biomoleculas (por ejemplo, insulina) en formulaciones liquidas. |
| EP2325205A3 (en) | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| KR20020066778A (ko) | 2001-02-13 | 2002-08-21 | 한국과학기술연구원 | 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법 |
| SE0101256D0 (sv) | 2001-04-06 | 2001-04-06 | A & Science Invest Ab | Treatment of low back pain |
| US20030012786A1 (en) | 2001-05-25 | 2003-01-16 | Teoh Leah S. | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients |
| US20040156835A1 (en) | 2001-05-30 | 2004-08-12 | Taiji Imoto | Protein preparation |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| CA2385745C (en) * | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| CA2448218C (en) | 2001-06-21 | 2012-05-29 | Genentech, Inc. | Sustained release formulation |
| JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ，インコーポレイティド | ＩｇＧ抗体の安定な凍結乾燥医薬製剤 |
| TWI327597B (en) * | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| EP1428537B1 (en) | 2001-08-29 | 2008-11-19 | Chugai Seiyaku Kabushiki Kaisha | Stabilized preparations containing antibody |
| US6818613B2 (en) | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| GB0202633D0 (en) | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
| DE60334678D1 (de) | 2002-02-14 | 2010-12-09 | Chugai Pharmaceutical Co Ltd | Antikörper enthaltende pharmazeutische lösungen |
| US20030161828A1 (en) | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
| EP1478394B1 (en) | 2002-02-27 | 2008-07-30 | Immunex Corporation | Stabilized TNFR-Fc composition comprising arginine |
| US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US20040009172A1 (en) | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| EP1551875A4 (en) | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF |
| CA2492143A1 (en) | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
| MY151032A (en) | 2002-07-19 | 2014-03-31 | Abbott Lab S A | Treatment of tnf? related disorders |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| CA2508375C (en) * | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| WO2006041970A2 (en) | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
| KR20150055116A (ko) | 2005-05-16 | 2015-05-20 | 애브비 바이오테크놀로지 리미티드 | 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도 |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| NZ567286A (en) | 2005-11-01 | 2012-03-30 | Abbott Biotechnolgy Ltd | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
| NZ611859A (en) | 2006-04-05 | 2014-12-24 | Abbvie Biotechnology Ltd | Antibody purification |
| US20090317399A1 (en) | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| WO2007120656A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| CN103276033A (zh) | 2006-09-13 | 2013-09-04 | 雅培制药有限公司 | 细胞培养改良 |
| EP2165194A4 (en) | 2007-05-31 | 2010-09-08 | Abbott Lab | BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES |
| WO2008150490A2 (en) | 2007-06-01 | 2008-12-11 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriasis and crohn's disease |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| CA2693771A1 (en) | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor |
| TWI543768B (zh) | 2007-11-30 | 2016-08-01 | 艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| CA2710333A1 (en) | 2008-01-03 | 2009-07-09 | Abbott Biotechnology Ltd. | Predicting long-term efficacy of a compound in the treatment of psoriasis |
| WO2009091912A2 (en) | 2008-01-15 | 2009-07-23 | Abbott Laboratories | Improved mammalian expression vectors and uses thereof |
| SG2013054218A (en) | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
-
2003
- 2003-10-23 MY MYPI20034055 patent/MY150740A/en unknown
- 2003-10-24 KR KR1020107026478A patent/KR20110000757A/ko not_active Ceased
- 2003-10-24 EP EP03809644A patent/EP1578439B1/en not_active Expired - Lifetime
- 2003-10-24 UY UY28041A patent/UY28041A1/es not_active Application Discontinuation
- 2003-10-24 WO PCT/US2003/033973 patent/WO2004037205A2/en not_active Ceased
- 2003-10-24 PE PE2003001080A patent/PE20040751A1/es not_active Application Discontinuation
- 2003-10-24 AT AT03809644T patent/ATE517632T1/de active
- 2003-10-24 KR KR1020147025727A patent/KR20140117697A/ko not_active Withdrawn
- 2003-10-24 PL PL376705A patent/PL213215B1/pl unknown
- 2003-10-24 EP EP10181959A patent/EP2295071A1/en not_active Withdrawn
- 2003-10-24 DK DK03809644.2T patent/DK1578439T3/da active
- 2003-10-24 PT PT03809644T patent/PT1578439E/pt unknown
- 2003-10-24 NZ NZ539332A patent/NZ539332A/en not_active IP Right Cessation
- 2003-10-24 MX MXPA05004344A patent/MXPA05004344A/es active IP Right Grant
- 2003-10-24 KR KR1020117030418A patent/KR20120013443A/ko not_active Abandoned
- 2003-10-24 NZ NZ585493A patent/NZ585493A/en not_active IP Right Cessation
- 2003-10-24 SI SI200332033T patent/SI1578439T1/sl unknown
- 2003-10-24 TW TW102126999A patent/TW201345552A/zh unknown
- 2003-10-24 CN CN201310140246.4A patent/CN103623408A/zh active Pending
- 2003-10-24 TW TW100105907A patent/TWI423817B/zh not_active IP Right Cessation
- 2003-10-24 CA CA002497909A patent/CA2497909A1/en not_active Abandoned
- 2003-10-24 PL PL398520A patent/PL398520A1/pl unknown
- 2003-10-24 CN CNA2003801074411A patent/CN1732015A/zh active Pending
- 2003-10-24 JP JP2004547181A patent/JP5594803B2/ja not_active Expired - Fee Related
- 2003-10-24 US US10/693,233 patent/US8846046B2/en not_active Expired - Lifetime
- 2003-10-24 AU AU2003301522A patent/AU2003301522B8/en not_active Ceased
- 2003-10-24 NZ NZ596945A patent/NZ596945A/xx not_active IP Right Cessation
- 2003-10-24 AR ARP030103906A patent/AR045710A1/es unknown
- 2003-10-24 BR BR0315597-8A patent/BR0315597A/pt not_active IP Right Cessation
- 2003-10-24 KR KR1020057007014A patent/KR20050083805A/ko not_active Ceased
- 2003-10-24 ES ES03809644T patent/ES2370351T3/es not_active Expired - Lifetime
- 2003-10-24 EP EP10182448A patent/EP2332565A1/en not_active Withdrawn
- 2003-10-24 TW TW092129599A patent/TWI361696B/zh not_active IP Right Cessation
-
2004
- 2004-02-11 SA SA04240497A patent/SA04240497A/ar unknown
-
2005
- 2005-04-13 ZA ZA200502983A patent/ZA200502983B/en unknown
-
2010
- 2010-07-14 AR ARP100102561A patent/AR077573A2/es unknown
- 2010-07-29 AU AU2010206042A patent/AU2010206042B2/en not_active Ceased
-
2011
- 2011-07-22 JP JP2011161229A patent/JP5676386B2/ja not_active Expired - Fee Related
-
2014
- 2014-02-19 US US14/183,845 patent/US20140200332A1/en not_active Abandoned
- 2014-09-08 JP JP2014181968A patent/JP2015028040A/ja active Pending